109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
C 反应蛋白、降钙素原和干扰素α在新冠肺炎中的预后价值及其与泛凋亡的关系：中国广西的一项队列研究
Authors Ning LJ, Liu MQ, Jiang ZS, Wu XQ, Wang XY, Qin XJ, Gan T, Tang SF, Lv GY, Wu Y
Received 29 April 2025
Accepted for publication 14 October 2025
Published 6 November 2025 Volume 2025:18 Pages 15527—15542
DOI https://doi.org/10.2147/JIR.S530980
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Ning Quan
Li-jun Ning,1,* Mei-Qiong Liu,2,* Zhong-Sheng Jiang,3,* Xian-Qiu Wu,4 Xiao-Yuan Wang,2 Xue-Jun Qin,5 Tao Gan,6 Shi-Fu Tang,7 Guang-Yu Lv,2 Ying Wu1
1Liuzhou Key Laboratory of Infection Disease and Immunology, Research Center of Medical Sciences, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 2Department of Critical Care Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 3Department of Infectious Diseases Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 4Department of Cardiothoracic Surgery, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 5Department of Respiratory and Critical Care Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 6Department of Emergency Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 7Department of Medical laboratory Science, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ying Wu, Research Center of Medical Sciences, Liuzhou People’s Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China, Email aqiwuying@163.com Guang-Yu Lv, Department of Critical Care Medicine, Liuzhou People’s Hospital affiliated to Guangxi Medical University, Liuzhou, 545006, Guangxi, People’s Republic of China, Email lgy197823@163.com
Objective: Numerous biomarkers of COVID-19 severity have been studied recently, while their relevance in the post-COVID-19 era requires further validation. This study sought to identify reliable biomarkers within a single cohort through a comprehensive comparative analysis and to investigate the underlying molecular mechanisms.
Material and Methods: In this prospective, observational cohort study, we comprehensively assessed 41 markers in 97 COVID-19 pneumonia patients and 53 healthy volunteers. Receiver operating characteristics and Kaplan–Meier curves were plotted to determine the predictive value of effective biomarkers. Subsequently, flow cytometry, immunofluorescence, and Western blot analysis were conducted to evaluate the inflammatory cell death induced by the identified biomarkers in peripheral blood cells.
Results: Based on the screening, plasma IL-6, IL-8, IL-10, IFN-α, PCT, and CRP at hospital admission were highly associated with disease severity (P < 0.001). A pairwise combination of CRP, PCT, and IFN-α could induce PANoptosis in neutrophils, lymphocytes, and platelets.
Conclusion: The value of IL-6, IL-8, IL-10, IFN-α, PCT, and CRP in predicting the severity of COVID-19 was further verified in our study, and superior to novel biomarkers. Our data confirmed for the first time that CRP, PCT, and/or IFN-α triggers PANoptosis in lymphocytes, neutrophils, and platelets, which may prompt severe progression in COVID-19 patients.
Keywords: COVID-19, C-reactive protein, procalcitonin, interferon alpha, PANoptosis
1Liuzhou Key Laboratory of Infection Disease and Immunology, Research Center of Medical Sciences, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 2Department of Critical Care Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 3Department of Infectious Diseases Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 4Department of Cardiothoracic Surgery, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 5Department of Respiratory and Critical Care Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 6Department of Emergency Medicine, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China; 7Department of Medical laboratory Science, Liuzhou People’s Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ying Wu, Research Center of Medical Sciences, Liuzhou People’s Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People’s Republic of China, Email aqiwuying@163.com Guang-Yu Lv, Department of Critical Care Medicine, Liuzhou People’s Hospital affiliated to Guangxi Medical University, Liuzhou, 545006, Guangxi, People’s Republic of China, Email lgy197823@163.com
Objective: Numerous biomarkers of COVID-19 severity have been studied recently, while their relevance in the post-COVID-19 era requires further validation. This study sought to identify reliable biomarkers within a single cohort through a comprehensive comparative analysis and to investigate the underlying molecular mechanisms.
Material and Methods: In this prospective, observational cohort study, we comprehensively assessed 41 markers in 97 COVID-19 pneumonia patients and 53 healthy volunteers. Receiver operating characteristics and Kaplan–Meier curves were plotted to determine the predictive value of effective biomarkers. Subsequently, flow cytometry, immunofluorescence, and Western blot analysis were conducted to evaluate the inflammatory cell death induced by the identified biomarkers in peripheral blood cells.
Results: Based on the screening, plasma IL-6, IL-8, IL-10, IFN-α, PCT, and CRP at hospital admission were highly associated with disease severity (P < 0.001). A pairwise combination of CRP, PCT, and IFN-α could induce PANoptosis in neutrophils, lymphocytes, and platelets.
Conclusion: The value of IL-6, IL-8, IL-10, IFN-α, PCT, and CRP in predicting the severity of COVID-19 was further verified in our study, and superior to novel biomarkers. Our data confirmed for the first time that CRP, PCT, and/or IFN-α triggers PANoptosis in lymphocytes, neutrophils, and platelets, which may prompt severe progression in COVID-19 patients.
Keywords: COVID-19, C-reactive protein, procalcitonin, interferon alpha, PANoptosis